Genscript Biotech Corp. is a leading pharmaceutical company based in China, specializing in life science research services and products. Known for its expertise in gene synthesis, Genscript Biotech caters to academics, biotech companies, and pharmaceutical companies globally. The company also offers biologics development services through its ProBio brand and industrial enzymes through its Bestzyme brand. With a medium ESG risk rating score of 21.9, Genscript Biotech is a key player in the industry. Additionally, the company holds a majority stake in Nasdaq-listed Legend Biotech, a company focused on developing a cutting-edge CAR-T treatment for multiple myeloma. More than two-thirds of Genscript's value is attributed to its ownership in Legend Biotech.